IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
Adverse events following statin-fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials
Lee, Chongyou; Geng, Qiang; Ren, Jingyi; Chen, Hong; Liang, Wenqing
关键词Adverse Events Fenofibrate Meta-analysis Statin
刊名CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
2013-03-01
DOI10.1111/1440-1681.12053
40期:3页:219-226
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy ; Physiology
资助者National Natural Science Foundation of China ; National Natural Science Foundation of China
研究领域[WOS]Pharmacology & Pharmacy ; Physiology
关键词[WOS]TYPE-2 DIABETES-MELLITUS ; COMBINED HYPERLIPIDEMIA ; DOUBLE-BLIND ; COMBINATION THERAPY ; PLUS FENOFIBRATE ; LIPID THERAPY ; DYSLIPIDEMIA ; SIMVASTATIN ; ATORVASTATIN ; TOLERABILITY
英文摘要

The combination of fenofibrate with statins is a beneficial therapeutic option for patients with mixed dyslipidaemia, but concerns about adverse events (AEs) make physicians reluctant to use this combination therapy. Medline, Embase and the Cochrane Library were searched to identify 13 randomized controlled trials, involving 7712 patients, of statinfenofibrate therapy versus statin alone for review. There were significant decreases in low-density lipoproteincholesterol, triglycerides and total cholesterol and increases in high-density lipoproteincholesterol in patients receiving combination therapy compared with statin therapy alone. The incidence of aminotransferase elevations in the fenofibratestatin therapy group was significantly higher than in the statin monotherapy group (odds ratio (OR), 1.66; 95% confidence interval (CI) 1.172.37; P<0.05). The incidence of elevated creatine kinase levels (OR 0.88; 95% CI 0.631.23; 0.05), muscle-associated AEs (OR 0.98; 95% CI 0.881.09; 0.05) and withdrawals attributed to liver and muscle dysfunction did not differ significantly between the two groups. The efficacy of fenofibrate+standard-dose statin and incidence of AEs in the fenofibrate+standard-dose statin group were almost identical to those in the fenofibratestatin group. In conclusion, combination therapy improves the blood lipid profile of patients. Fenofibratestatin combination therapy appears to be as well tolerated as statin monotherapy. Physicians should consider fenofibratestatin combination therapy in patients but monitor aminotransferase levels to avoid hepatic complications.

语种英语
所属项目编号NSFC 30570712
资助者National Natural Science Foundation of China ; National Natural Science Foundation of China
WOS记录号WOS:000315447000008
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50287
专题北京大学第二临床医学院_心血管内科
作者单位Peking Univ, Dept Cardiol, Peoples Hosp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Lee, Chongyou,Geng, Qiang,Ren, Jingyi,et al. Adverse events following statin-fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials[J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY,2013,40(3):219-226.
APA Lee, Chongyou,Geng, Qiang,Ren, Jingyi,Chen, Hong,&Liang, Wenqing.(2013).Adverse events following statin-fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials.CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY,40(3),219-226.
MLA Lee, Chongyou,et al."Adverse events following statin-fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials".CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY 40.3(2013):219-226.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lee, Chongyou]的文章
[Geng, Qiang]的文章
[Ren, Jingyi]的文章
百度学术
百度学术中相似的文章
[Lee, Chongyou]的文章
[Geng, Qiang]的文章
[Ren, Jingyi]的文章
必应学术
必应学术中相似的文章
[Lee, Chongyou]的文章
[Geng, Qiang]的文章
[Ren, Jingyi]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。